Physician profile
Lance Brandon Abernathy
NPI 1063776318
$4,033.37
in general payments reported to CMS, 2019-2025
21 companies · $648 in 2025
The $648 reported for 2025 was more than what 89% of Vision Therapy providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $303 · 2021: $297 · 2022: $788 · 2023: $767 · 2024: $675 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,090.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $950.80 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $836.17 | 2019-2025 | Total30, Precision 1, Dailies |
| Visioneering Technologies, INC. | $340.96 | 2024 | |
| Novartis Pharmaceuticals Corporation | $238.98 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $231.41 | 2022-2024 | Infuse, Vyzulta |
| Allergan, INC. | $227.42 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $166.97 | 2019-2021 | |
| Shire North American Group INC | $121.66 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $116.13 | 2024-2025 | Xdemvy |
| Coopervision INC. | $111.85 | 2019-2023 | Myday Contact Lens, Misight Contact Lens |
| Astellas Pharma US INC | $104.38 | 2024-2025 | Izervay |
| Optovue, INC. | $101.41 | 2019 | |
| Oyster Point Pharma, INC. | $94.14 | 2022-2024 | Tyrvaya, Ryzumvi |
| Abb Con-Cise Optical Group LLC | $77.91 | 2019-2023 | Spectacle Lenses, Contact Lens |
| Harrow Eye, LLC | $71.86 | 2025 | Vevye |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $71.61 | 2022 | |
| Glaukos Corporation | $71.43 | 2019 | |
| Kala Pharmaceuticals, INC. | $51.94 | 2021-2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Optos, INC. | $14.44 | 2022 | |
| Integra Lifesciences Corporation | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Abernathy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.